Andrew Obenshain | Head Of Europe
Bluebird Bio

Andrew Obenshain, Head Of Europe, Bluebird Bio

Andrew Obenshain is Head of Europe at bluebird bio, a biotech company focused on developing potentially transformative cell & gene therapies for severe genetic and rare diseases.
Before taking up this role in 2016, he was at Shire in Paris, France where he was the general manager of France and Benelux overseeing a portfolio including seven rare disease products. Prior to Shire, Andrew spent eight years at Genzyme and Sanofi holding roles of increasing responsibility in business development, marketing and global commercial operations.
Mr. Obenshain received his MBA from Northwestern University’s Kellogg School of Management, and his B.A. in genetics, cell and developmental biology from Dartmouth College.


Conference Day 1: Thursday 16th May 2019 @ 09:30

(ex vivo) Gene edited therapeutics and (in vivo) gene therapy: how can gene technology be used now and, in the future, to treat and cure diseases in the clinic

  • How does gene editing apply to the clinic?
  • How is it currently being applied?
  • How can we improve delivery of AAVs into the cell?
  • Improving the volume of viral particles: what stages do we need to cover to get to a commercial scale?
  • Moving into larger diseases from rare diseases, what challenges need to be overcome?
  • Risk/benefit acceptance of the general population and the medical system.
  • What is the real risk of CRISPR causing cancer as published by Novartis and KI?
  • How do we want to use it in the future and what challenges need to be overcome to do so? (immunogenicity, off target effects and efficacy, being vigilant with safety profiles, potency and manufacturing, moving towards direct, in vivo [bluebird bio live delivery usingnanoparticles], viral and non-viral)
  • How do you move towards that goal in a way that engages stakeholders? Applications

Conference Day 1: Thursday 16th May 2019 @ 14:15

Getting genetic therapies from the bench to the bedside: Meeting the challenges of commercialisation

· What are the biggest challenges to making gene therapy commercially viable· What system change is needed· What have we learned as an industry so far
last published: 18/Mar/19 11:45 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.


Erica Baeta 
+44 (0)207 092 1152


Jessica Robinson 
t/ +44 (0)207 092 1150


Issa Mauthoor 
+44 (0)207 092 1257